Jpmorgan Chase & CO Metacrine, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.1 Trillion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.43 - $0.55 $1 - $1
3 New
3 $0
Q2 2022

Aug 11, 2022
SELL
$0.36 - $0.63 $373 - $653
-1,038 Closed
0 $0
Q1 2022

May 11, 2022
BUY
$0.43 - $0.7 $446 - $726
1,038 New
1,038 $1,000

Others Institutions Holding MTCR

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Metacrine, Inc.

MTCR Quotes by TradingView
  • Ticker MTCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,569,500
  • Description
  • Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
More about MTCR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email